布地奈德与地塞米松直肠用药治疗远端溃疡性结直肠炎的临床疗效对比

To compare the clinical efficacy of budesonide and dexamethasone treatment of rectal distal ulcerative colitis

目的比较远端溃疡性结直肠炎者应用地塞米松和布地奈德直肠用药医治的临床疗效。方法选取远端溃疡性结直肠炎106例患者资料予以分析,依据直肠用药时所用不同药物分成对照组及观察组,对前者实施地塞米松医治,对后者实施布地奈德医治,记录且对比两组临床疗效,包括症状评分、免疫组化、不良反应。结果观察组脓血便[(0.43±0.20)vs(1.50±0.35)]、腹泻[(0.40±0.15)vs(1.48±0.32)]、腹痛[(0.36±0.18)vs(1.52±0.38)]症状评分均比对照组低;观察组医治后ICAM-1[(230.10±16.40)ng/L vs(250.50±25.50)ng/L]、P-sel[(18.26±3.10)ng/L vs(24.30±4.03)ng/L]水平表达强度的减弱程度均比对照组高;观察组总不良反应概率(3.39%)比对照组(19.15%)低,上述两组各指标比较,差异具有统计学意义(P<0.05)。结论布地奈德直肠用药应用于远端溃疡性结直肠炎治疗中的疗效显著,有利于改善患者临床症状和炎症反应。

Objective To compare the distal ulcerative colitis were treated with dexamethasone and budesonide rectal administration clinical curative effect. Methods 106 cases of distal ulcerative colitis patients by analysis of rectal medication with different drugs were divided into control group and observation group on the basis of the implementation of the former, dexamethasone treatment, budesonide treatment on implementation of the latter, record and compare the clinical efficacy between two groups, including the symptom score, immunohistochemistry, adverse reaction. Results The observation group [(0.43 ± 0.20) vs(1.50 ± 0.35)], [(0.40 ± 0.15) vs(1.48 ± 0.32)], abdominal pain(0.36 ± 0.18) vs(1.52 ± 0.38)] symptom scores were lower than the control group; the observation group after treatment ICAM-1 [(230.10±16.40)ng/L vs(250.50 ± 25.50)ng/L], P-sel[(18.26 ± 3.10)ng/L vs(24.30 ± 4.03)ng/L] expression level decreased the intensity degree were higher than the control group; the observation group the total adverse reaction probability(3.39%) than the control group(19.15%), comparing the two groups, statistically significant differences(P<0.05). Conclusion Budesonide distal rectal medication used in the treatment of ulcerative colitis curative effect is remarkable, is conducive to the improvement of clinical symptoms and inflammatory reaction of patients.